Hear expert insights on the global burden and epidemiology of hepatitis delta virus (HDV) and the challenges associated with accurately diagnosing the population with HDV.
Hear expert insights on whom to test for hepatitis delta virus, how to test, and limitations of current testing options and approaches.
Hear patient insights on the delay in diagnosis and impact of living with hepatitis delta.
Hear expert insights on current treatments for HDV and the importance of developing new agents that are better tolerated and have improved efficacy.
Hear expert insights on the role in therapy of new and investigational treatments for patients with HDV.
Hear expert insights on the role of advanced practice providers in the management of hepatitis delta virus infections, including medication monitoring and patient education.
Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. Listen to experts discuss a call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta.
Few treatment options exist for HDV, but many promising investigational agents are on the horizon. Listen to experts discuss what questions still need to be answered to optimize treatment of HDV with current―as well as new and emerging―agents.
The hepatitis delta virus (HDV) only coexists in patients chronically infected with hepatitis B virus (HBV). Listen to experts discuss steps to take for monitoring and treating both forms of viral hepatitis.
Several emerging agents will soon be available for the treatment of hepatitis delta virus (HDV). Hear experts discuss rational use and combinations of new agents to treat patients with HDV.
Listen as 2 experts discuss the importance of increasing healthcare professional and patient awareness of HDV to ensure that at-risk patients receive screening and then treatment and monitoring following a positive test.
Your patient tests positive for hepatitis delta virus (HDV). Now what? Listen as 2 experts discuss challenges and opportunities in linking patients with HDV to care.
Comprehensive slideset updated regularly to include the latest data and guideline updates for hepatitis delta virus (HDV).
To link patients with hepatitis delta virus to care, we first must be able to identify them.
Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.
My thinking about HDV testing recommendations has shifted in recent years. Here’s why.
Our current treatment option for hepatitis delta virus is pegylated interferon alfa, which does not have robust efficacy data and is not always well tolerated—but many novel investigational agents are being studied to provide more efficacious, better tolerated therapies